Mostrando 4 resultados de: 4
Filtros aplicados
CYP2D6 genotyping for psychiatric patients treated with risperidone: Considerations for cost-effectiveness studies
ArticleAbstract: In order to ascertain data availability and feasibility for conducting cost-effectiveness studies inPalabras claves:adverse drug reactions, Antipsychotic, cost-effectiveness, CYP2D6, polymorphisms, RisperidoneAutores:Adrián LLerena, De Leon J., de Mesa E.G., Gurwitz D., Ibarreta D., Kirchheiner J., Rodríguez-Antona C.Fuentes:scopusHigh frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
ArticleAbstract: Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have beenPalabras claves:Autores:Adrián LLerena, Apellániz-Ruiz M., Carracedo Á., Cascón A., Comino-Méndez I., Currás-Freixes M., De Cubas A.A., Grazina M., Ingelman-Sundberg M., Inglada-Pérez L., Mancikova V., Moya G.E., Naranjo M.E.G., Opocher G., Rasool M., Rebai A., Robledo M., Rodríguez-Antona C., Sánchez L., Taboada-Echalar P., Triki S.Fuentes:scopusProgress in pharmacogenetics: Consortiums and new strategies
ReviewAbstract: Pharmacogenetics (PGx), as a field dedicated to achieving the goal of personalized medicine (PM), isPalabras claves:next-generation sequencing (NGS) technologies, personalized medicine, pharmacogenetics, standardization; translationAutores:Adrián LLerena, Carracedo Á., Dopazo J., Latorre A., Maroñas O., Pirmohamed M., Rodríguez-Antona C., Siest G.Fuentes:scopusThe need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients
OtherAbstract:Palabras claves:drug prescription, health services, Implementation, pharmacogenetics, Pharmacogenomics, regulationAutores:Adrián LLerena, Manolopoulos V.G., Rodríguez-Antona C., Stanković S., Taron M., Van Schaik R.H.N.Fuentes:scopus